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Table 1
No serotherapy ATG Alemtuzumab p value
ADV 5.8 (0-16.9)% 0 % 29.3 (5.1-53.5)% 0.056
CMV 5.8 (0-16.9)% 20 (0-44.8)% 34 (9.7-58.3)% 0.08
EBV 5.8 (0-16.9)% 18.2 (0-40.5)% 0% .25
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Unrelated cord blood transplant (UCBT) is an established
graft source for HSCT especially for minorities. Use of sero-
therapy such as anti-thymocyte globulin (ATG) and alemtu-
zumab is associated with delayed immune reconstitution,
leading to increased viral reactivation especially when the
donors are virus naïve. Therefore, we studied the impact of
serotherapy along with other factors on viral reactivation
(EBV, CMV, adenovirus (ADV)), GVHD, and transplant-related
mortality (TRM) at 100 days in pediatric patients after UCBT.
Statistics used were chi-squared test, and Kaplan-Meier cu-
mulative incidence (CI) with log-rank. For CI of viral reac-
tivation, patients were censored if they died or reached day
100 before viral reactivation. All patients had weekly GVHD
grading using Glucksberg criteria and weekly PCR for the 3
viruses. Reactivation was deﬁned as blood viral PCR>1000
copies/ml. This retrospective study evaluated 47 consecutive
UCBTs performed from 2006-2014. Median age was 3 years
(range 0-17). Diagnoses: leukemia (19), immunodeﬁciency
(10), hemoglobinopathy (7), bone marrow failure (6), meta-
bolic disorder (3), andhistiocytic disorder (2). 21 patients
received myeloablative conditioning (MAC) and 26 reduced-
intensity conditioning (RIC). Median degree of HLA matching
was 5/6 (4-6/6). Pre-transplant serotherapy was used in 30
patients (15alemtuzumab, 15 ATG) irrespective of HLA
matching. Median cell dose was 6.15x107(0.9e18.9x107)
TNC/kg. Among all variables evaluated, underlying diagnosis
was the only one associated with development of  grade 2
acute GVHD, occurring predominantly in leukemia patients
(p¼0.048). For viral reactivation, the conditioning regimen
inﬂuenced CMV reactivation, with signiﬁcantly more CMV
reactivations in MAC recipients (p ¼ 0.044), and more EBV
reactivations in RIC recipients (p ¼ 0.046). Conditioning
regimen did not inﬂuence ADV reactivation. For ADV, only
the type of serotherapy had a strong association with reac-
tivation, with more ADV infections in patients who received
alemtuzumab (p ¼ 0.044). No variable had a relationship
with TRM. We then explored the day 100 CI of viral reac-
tivation, by type of serotherapy (Table 1). There was a trend
towards higher CI of ADV reactivation in patients who
received alemtuzumab. We conclude that in pediatric UCBT
patients, while the impact of serotherapy on acute GVHD is
unclear, it does have a major impact on viral reactivation.
Speciﬁcally, alemtuzumab appears to have more impact on
ADV reactivation than ATG. While further data will be
collected on the morbidity and mortality associated with
these infections, novel therapies to treat viruses in the
context of serotherapy-treated UCBT recipients are needed.283
Targeted Next-Generation Sequencing Panel for Clinical
Diagnostic in Inherited Bone Marrow Failure Syndromes
Beneﬁt for Pediatric HSCT
Jing Chen 1,2, Chengjuan Luo 3, Jiangmin Wang 4,
Changying Luo 5, Jian Wang 6, Qihua Fu 6, Yiping Shen 7.
1 Shanghai Jiaotong University, School of Medicine, Shanghai,China; 2 Key Laboratory of Pediatric Hematology Oncology
National Health and Family Planning Commission, Shanghai,
China; 3 Shanghai Children’s Medical Center, Shanghai, China;
4 Shanghai Jiaotong University School Of Medicine Shanghai
Children’s Medical Center, Shanghai, China; 5 Shanghai
Jiaotong University,School Of Medicine, Shanghai Children’s
Medical Center, Shanghai, China; 6Molecular Diagnostic
Laboratory, Shanghai Children’s Medical Center, Shanghai
Jiaotong University School of Medicine, Shanghai, China; 7 Gene
Diagnostic Laboratory, Boston Children’s Hospital, Harvard
Medical School, Boston, MA
Objective: Inherited bone marrow failure syndromes
(IBMFS) are a heterogeneous group of genetic disorders
characterized by bone marrow failure, congenital anomalies,
and an increased risk of malignant disease. Because of
phenotypic variability, diagnosis can be challenging for cli-
nicians. This study is aimed to develop a targeted panel-
based Next Generation Sequencing (NGS) pipeline to clinical
diagnosis in IBMFS patients.
Method: Agilent Haloplex method was used for target cap-
ture the IBMFS Library of known genes and related genes,
Illumina platformwas used for high-throughput sequencing,
sequencing data was aligned by NextGENe software, the
variants were ﬁltered and interpretation by the online tool
Ingenuity Variant Analysis, and Sanger sequencing was used
to conﬁrm the variations. 21 patients with suspected IBMFS
were studied and DNA frommembers of each pedigree were
collected for this study.
Results: More than 95% of the sequencing reads aligned to
human genome reference sequence and more than 85% of
the reads are in the target sequence. The 20 coverage area is
>95% and the uniformity is >85%. Of the 21 patients with
suspected IBMFS, pathogenic mutations have been identiﬁed
in 12 patients, including 6 cases with Fanconi anemia (FA), 2
cases of Dyskeratosis congenital (DC), 2 cases of Severe
congenital neutropenia (SCN), 1 case of Diamond-Blackfan
anemia (DBA), and 1 case of Shwachman-Diamond syn-
drome (SDS). After hematopoietic stem cell transplantation,
5 patients were successfully cured. Prenatal diagnosis has
been successfully performed in 3 families.
Conclusion: This study successfully established the target
panel sequencingmethod tomoleculardiagnosis of IBMFS. The
clinical results showed that our method can effectively detect
and identify pathogenic genes in monogenic disorders and to
provide a strong basis for completely cure and prenatal diag-
nosis, because the efﬁciency of captured target region is
excellent, the quality of sequencing data is reliable, and the
analysis by the bioinformatics software is very comprehensive.284
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Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S214Background: Alternate donor (AD) hematopoietic stem cell
transplantation (HSCT) for children with severe aplastic
anemia (SAA) remains challenges mainly associated with
graft failure and Graft versus Host Disease (GVHD). So it has
been considered in the second choice of treatment status.
But the survival outcomes from AD HSCT in childhood SAA
have improved steadily over the past decade. To answer the
question whether the AD HSCT can be the ﬁrst line therapy
for SAA children we start this single center prospective
upfront AD HSCT study.
Methods: Based on the success of the AD HSCT for children
with SAA previously in our center, the upfront AD HSCT
protocols were approved by the local Ethics Committees. This
trail was registered in ChiCTR (www.chictr.org) in 2010.
Fludarabine (180mg/m2-200mg/m2) +Cyclophosphamide
(120mg/kg) +Anti-thymocyte globulin (ATG, thymoglobulin
10mg/kg) +TBI 3GY were the conditioning regimen and pe-
ripheral blood stem cell was the stem cell source for all the
HSCT children.
Results: 56 children with acquired SAA (include 15VSAA)
were recruited in this upfront AD HSCT study in our center
between Jan 2010 to Jun 2014 with the average age 7.5 (1.8-
17) years old. 21 patients with 10/10 matched unrelated
donor (MUD), 23 patients with 8-9/10mismatched unrelated
donor (MMUD) and 9 patients with 5-8/10 mismatched
related donor (MMRD). All patients did not receive ATG
before HSCT. The average interval from diagnosis to HSCT
was 6.5 (1-102) months. The median nucleated cell doses
were (11.23.4)108/kg and the CD34+ cell doses were
(4.732.37)106/kg. Except 1 graft failure (rescued by sec-
ond HSCT) 55 (98.2%) were engrafted with neutrophil and
platelet recovery occurring at a median of 12 days (range, 9-
18) and 14 (7-68) post-transplant. The cumulative incidence
was 39% and 7% for grade I-II and III-IV acute GVHD, 19% and
2% for mild and moderate chronic GVHD. Compared to our
previous study this intensiﬁed conditioning regimen with
lower graft failure but high post-transplant lymphoprolifer-
ative disease (PTLD). After median follow up 21.75 (2.2-54)
months, 4 of 56 patients died (2 died of PTLD,1 died of severe
aGVHD and another 1 died of CNS infection). 2 patients
suffered poor graft function with long interval from diag-
nosis to HSCT (84 months and 102 months respectively). 5
VSAA patents under uncontrolled infection were rescued by
AD HSCT. The estimated 5-year OS and FFS of the entire
cohort was 92.6% and 88.6%, with no difference between theFigure 1.MUD, MMUD and MMRD cohort (97.7%, 92.3% and 88.9%
respectively).
Conclusions: These excellent outcomes suggest that unma-
nipulated AD PBSC is a good HSCT source for children with
SAA. It’s reasonable to consider AD HSCT as ﬁrst line therapy
for SAA children if suitable donor can be found quickly. HSCT
rescued therapy was important for some under uncontrolled
infection VSAA children. Better strategies are required to
prevent PTLD.285
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Thyroid dysfunction is a known complication following he-
matopoietic stem cell transplantation (HSCT) in children.
Most reports in children describe hypothyroidism related to
pre-transplant conditioning regimens, especially total body
irradiation (TBI). We now report the development of post-
transplant thyroid dysfunction on 8 children that developed
hyperthyroidism following HSCT. Three patients were
transplanted for metabolic diseases (two with Sanﬁlippo
Syndrome and one with Adrenal Leukodystrophy, one for
Acute Myelogenous Leukemia, one for Kostman’s Syndrome,
one for Purine Nucleotide Phosphorylase Deﬁciency (PNP),
one for Paroxysmal Nocturnal Hemoglobinuria (PNH) and
one for Chronic Granulomatous Disease (CGD). Five children
were transplanted with Unrelated Umbilical Cord Blood
(URCB), one with matched sibling transplant and two with
adult Matched Unrelated Donor (MUD) transplant. Four of
the ﬁve patients receiving cord blood transplants received
myloablative therapy with Busulfan, Cytoxan and ATG; one
of the URCB patients and one MUD transplant patient
received Fludarabine, Busulfan, Cytoxan and ATG and the
other MUD transplant received Fludarabine, Cytoxan and
two doses of TBI for conditioning. The patient that received
the matched sibling transplant was prepared for transplant
with Busulfan and Melphalan. The onset of hyperthyroidism
ranged between 9 months and 5 years post transplant.
Five patients were off of immunosuppression when
